Note: Descriptions are shown in the official language in which they were submitted.
CA 02528849 2005-12-06
PRD 2469f
-1-
QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
The present invention relates to the use of quinoline derivatives for the
manufacture of
a medicament for the treatment of a bacterial infection.
Resistance to first-line antibiotic agents is an emerging problem. Some
important
examples include penicillin-resistant Streptococcus pneumoniae, vancomycin-
resistant
enterococci, methicillin-resistant Staphylococcus aureus, multi-resistant
salmonellae.
The consequences of resistance to antibiotic agents are severe. Infections
caused by
resistant microbes fail to respond to treatment, resulting in prolonged
illness and greater
risk of death. Treatment failures also lead to longer periods of infectivity,
which
increase the numbers of infected people moving in the community and thus
exposing
the general population to the risk of contracting a resistant strain
infection.
Hospitals are a critical component of the antimicrobial resistance problem
worldwide.
The combination of highly susceptible patients, intensive and prolonged
antimicrobial
use, and cross-infection has resulted in infections with highly resistant
bacterial
pathogens.
Self-medication with antimicrobials is another major factor contributing to
resistance.
Self-medicated antimicrobials may be unnecessary, are often inadequately
dosed, or
may not contain adequate amounts of active drug.
Patient compliance with recommended treatment is another major problem.
Patients
forget to take medication, interrupt their treatment when they begin to feel
better, or
may be unable to afford a full course, thereby creating an ideal environment
for
microbes to adapt rather than be killed.
Because of the emerging resistance to multiple antibiotics, physicians are
confronted
with infections for which there is no effective therapy. The morbidity,
mortality, and
financial costs of such infections impose an increasing burden for health care
systems
worldwide.
Therefore, there is a high need for new compounds to treat bacterial
infections,
especially for the treatment of infections caused by resistant strains.
CA 02528849 2005-12-06
-2
WO 2004/011436 discloses substituted quinoline derivatives having activity
against
Mycobacteria, in particular against Mycobacterium tuberculosis. One particular
compound of these substituted quinoline derivatives is described in Science
(2005),
307, 223-227.
It has now been found that quinoline derivatives described in WO 2004/011436
also
show activity against other bacteria than Mycobacteria.
Therefore, the present invention relates to the use of a compound for the
manufacture
of a medicament for the treatment of a bacterial infection, said compound
being a
compound of formula
(R6),
R7
(R1)p R4 (I)
OH
\R5
R3
N R2
a pharmaceutically acceptable acid or base addition salt thereof, a
stereochemically
isomeric form thereof or a N-oxide form thereof, wherein
R1 is hydrogen, halo, polyhaloCi_6alkyl, Cioalkyl, Ar or Het;
is an integer equal to 1 or 2;
R2 is C1_6alkyloxy, C1_6alkyloxyCi_6alkyloxy or C1_6alkylthio;
R3 is Ar, Het or Het';
R4 and R5 each independently are hydrogen, Ci_6alkyl or benzyl; or
R4 and R5 together and including the N to which they are attached may form a
radical
selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl,
pyn-olyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl,
imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and
thiomorpholinyl, each of said rings may optionally be substituted with
C1_6a1ky1, halo, polyhaloCi_olkyl, hydroxy, hydroxyCl_6alkyl,
C1_6alkyloxy, amino, mono- or di(C1_6alkyl)amino, C1_6alkylthio,
Ci_6alkyloxyCi_6alkyl, C1_6alkylthioCi_6alkyl or pyrimidinyl;
R6 is hydrogen, halo, polyhaloC1_6alkyl, C1_6alkyl, Ci_6alkyloxy,
Ci_6alkylthio; or
CA 02528849 2005-12-06
-3
two vicinal R6 radicals may be taken together to form a bivalent radical of
formula
-CH=CH-CH=CH- ;
is an integer equal to 1 or 2;
R7 is hydrogen, C1_6alkyl, Ar, Het or Het';
Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl,
tetrahydronaphthyl, each homocycle may optionally be substituted with 1, 2 or
3 substituents, each substituent independently selected from the group of
hydroxy, halo, cyano, nitro, amino, mono- or di(Ci_6alkyl)amino, Ci_6alkyl,
hydroxyCi_6alkyl, C1_6alkyloxy, polyhaloCi_6alkyloxy,
C1_6alkyloxyCi_6alkyl, carboxyl, C1_6alkyloxycarbonyl, aminocarbonyl,
morpholinyl and mono- or di(Ci_6alkyl)aminocarbonyl;
Het is a monocyclic heterocycle selected from the group of N-
phenoxypiperidinyl,
piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl,
isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and
pyridazinyl; each monocyclic heterocycle may optionally be substituted with 1,
2 or 3 substituents, each substituent independently selected from the group of
halo, hydroxy, Ci_6alkyl, polyhaloCh6alkyl, hydroxyCi_6alkyl, Ci_6alkyloxy,
Ci_6alkyloxyCh6alkyl or Ar-C(=0)-;
Het' is a bicyclic heterocycle selected from the group of quinolinyl,
quinoxalinyl,
indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,
benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or
benzo[1,3]dioxoly1 ; each bicyclic heterocycle may optionally be substituted
with 1, 2 or 3 substituents, each substituent independently selected from the
group of halo, hydroxy, Ci_6alkyl, polyhaloCi_6alkyl, hydroxyCi_6alkyl,
Ci_6alkyloxy, Ci_6alkyloxyCl_6alkyl or Ar-C(=0)-;
provided that the bacterial infection is other than a Mycobacterial infection.
The present invention also relates to a method of treating a bacterial
infection in a
mammal, in particular a warm-blooded mammal, more in particular a human,
comprising administering an effective amount of a compound of the invention to
the
mammal.
As used hereinbefore or hereinafter Ci_6alkyl as a group or part of a group
defines
straight or branched chain saturated hydrocarbon radicals having from 1 to 6
carbon
atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl, pentyl, hexyl, 2-
methylbutyl
and the like.
CA 02528849 2005-12-06
-4
As used hereinbefore or hereinafter, the term (.0) forms a carbonyl moiety
when
attached to a carbon atom.
The term halo is generic to fluoro, chloro, bromo and iodo. As used in the
foregoing or
hereinafter, polyhaloCi_6alkyl as a group or part of a group is defined as
mono- or
polyhalosubstituted Ch6alkyl, for example, methyl with one or more fluoro
atoms, for
example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl and the like.
In case
more than one halogen atoms are attached to an alkyl group within the
definition of
polyhaloCi_oalkyl, they may be the same or different.
In the definition of Het or Het', or when R4 and R5 are taken together, it is
meant to
include all the possible isomeric forms of the heterocycles, for instance,
pyrrolyl
comprises 1H-pyrroly1 and 2H-pyrrolyl.
The Ar, Het or Het' listed in the definitions of the substituents of the
compounds of
formula (I) (see for instance R3) as mentioned hereinbefore or hereinafter may
be
attached to the remainder of the molecule of formula (I) through any ring
carbon or
heteroatom as appropriate, if not otherwise specified. Thus, for example, when
Het is
imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazoly1 and the like.
Lines drawn from substituents into ring systems indicate that the bond may be
attached
to any of the suitable ring atoms.
When two vicinal R6 radicals are taken together to form a bivalent radical of
formula
¨CH=CH-CH=CH-, this means that the two vicinal R6 radicals form together with
the
phenyl ring to which they are attached a naphthyl.
For therapeutic use, salts of the compounds of formula (I) are those wherein
the
counterion is pharmaceutically acceptable. However, salts of acids and bases
which are
are meant to comprise the therapeutically active non-toxic acid addition salt
forms
which the compounds of formula (I) are able to form. The latter can
conveniently be
CA 02528849 2005-12-06
-5
obtained by treating the base form with such appropriate acids as inorganic
acids, for
example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like;
sulfuric acid;
nitric acid; phosphoric acid and the like; or organic acids, for example,
acetic,
propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic,
The compounds of formula (I) containing acidic protons may be converted into
their
therapeutically active non-toxic metal or amine addition salt forms by
treatment with
appropriate organic and inorganic bases. Appropriate base salt forms comprise,
for
example, the ammonium salts, the alkali and earth alkaline metal salts, e.g.
the lithium,
The N-oxide forms of the present compounds are meant to comprise the compounds
of
The compounds of formula (I) may be converted to the corresponding N-oxide
forms
following art-known procedures for converting a trivalent nitrogen into its N-
oxide
CA 02528849 2005-12-06
-6
alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide;
appropriate
organic peroxides may comprise peroxy acids such as, for example,
benzenecarboper-
oxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-
chlorobenzenecarbo-
peroxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid,
alkylhydroperoxides, e.g.
t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower
alcohols, e.g.
ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone,
halogenated
hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
It will be appreciated that some of the compounds of formula (I) and their N-
oxides or
addition salts may contain one or more centres of chirality and exist as
stereochemically isomeric forms.
The term "stereochemically isomeric forms" as used hereinbefore or hereinafter
defines
all the possible stereoisomeric forms which the compounds of formula (I), and
their
N-oxides, addition salts or physiologically functional derivatives may
possess. Unless
otherwise mentioned or indicated, the chemical designation of compounds
denotes the
mixture of all possible stereochemically isomeric forms, said mixtures
containing all
diastereomers and enantiomers of the basic molecular structure.
In particular, stereogenic centers may have the R- or S-configuration;
substituents on
bivalent cyclic (partially) saturated radicals may have either the cis- or
trans-
configuration. Compounds encompassing double bonds can have an E (entgegen) or
Z
(zusammen) -stereochemistry at said double bond.
Stereochemically isomeric forms of the compounds of formula (I) are obviously
intended to be embraced within the scope of this invention.
Following CAS-nomenclature conventions, when two stereogenic centers of known
absolute configuration are present in a molecule, an R or S descriptor is
assigned (based
on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the
reference center. The configuration of the second stereogenic center is
indicated using
relative descriptors [R*,R* ] or [R*,S*], where R* is always specified as the
reference
center and [R*,R*] indicates centers with the same chirality and [R*,S*]
indicates
centers of unlike chirality. For example, if the lowest-numbered chiral center
in the
molecule has an S configuration and the second center is R, the stereo
descriptor would
be specified as S-[R*,S*]. If "a" and '73" are used : the position of the
highest priority
substituent on the asymmetric carbon atom in the ring system having the lowest
ring
number, is arbitrarily always in the "a" position of the mean plane determined
by the
ring system. The position of the highest priority substituent on the other
asymmetric
CA 02528849 2012-04-25
-7
carbon atom in the ring system relative to the position of the highest
priority substituent
on the reference atom is denominated "a", if it is on the same side of the
mean plane
determined by the ring system, or "f3", if it is on the other side of the mean
plane
determined by the ring system.
The terms "erythro" and "threo" can also be used as relative stereochemical
descriptors.
When a molecule bears two asymmetric carbons, 4 stereoisomers of the molecule
exist.
These isomers can be grouped in two couples of two enantiomers. A difference
between these two couples can be made using the notation erythro and threo
(initially
used for Sugar). The two asymmetric carbon atoms on the lateral chain of the
present
compounds, indicated by * in the structure below, are determinant for the
stereochemistry of the molecules. The relative configuration of the molecules
is
indicated as erythro if the groups, after being classified according to
priority rules
(rules of Cahn, Ingold, Prelog), scroll in the same direction when observed in
Newman
projection. The relative configuration of the molecules is indicated as threo
if the
groups, after being classified according to priority rules (rules of Cahn,
Ingold, Prelog),
scroll in the opposite direction when observed in Newman projection.
(R6),
(R1) R7 OH R4
p
õ =
R-
R3
N R2
Instead of erythro and threo, the terms "syn" and "anti" can also be used as
relative - =
stereodescriptors for the two couples of two enantiomers. To determine whether
a
molecule is syn or anti, the main chain of the molecule is drawn in the common
zigzag
manner. If the two main substituents (substituents are ranked according to
their priority
(Cahn Ingold Prelog rules)) are on the same side of the plane defined by the
main
chain, the stereochemistry is indicated as syn. If the two main substituents
are on the
opposite side of the plane defined by the main chain, the stereochemistry is
indicated as
anti.
The stereodescriptors cis, trans, E, Z, R, S, erythro, threo, syn, anti are
well known to a
person skilled in the art. Reference is also made to J.Am.Chem.Soc., 1982,
104, 5521-
5523.
CA 02528849 2005-12-06
-8
When a specific stereoisomeric form is indicated, this means that said form is
substantially free, i.e. associated with less than 50 %, preferably less than
20 %, more
preferably less than 10 %, even more preferably less than 5 %, further
preferably less
than 2 % and most preferably less than 1 % of the other isomer(s). Thus, when
a
compound of formula (I) is for instance specified as (ocS, 13R), this means
that the
compound is substantially free of the (ca, ps) isomer.
The compounds of formula (I) may be synthesized in the form of racemic
mixtures of
enantiomers which can be separated from one another following art-known
resolution
procedures. The racemic compounds of formula (I) may be converted into the
corresponding diastereomeric salt forms by reaction with a suitable chiral
acid. Said
diastereomeric salt forms are subsequently separated, for example, by
selective or
fractional crystallization and the enantiomers are liberated therefrom by
alkali. An
alternative manner of separating the enantiomeric forms of the compounds of
formula
(I) involves liquid chromatography using a chiral stationary phase. Said pure
stereochemically isomeric forms may also be derived from the corresponding
pure
stereochemically isomeric forms of the appropriate starting materials,
provided that the
reaction occurs stereospecifically. Preferably if a specific stereoisomer is
desired, said
compound will be synthesized by stereospecific methods of preparation. These
methods will advantageously employ enantiomerically pure starting materials.
The invention also comprises derivative compounds (usually called "pro-drugs")
of the
pharmacologically-active compounds according to the invention, which are
degraded in
vivo to yield the compounds according to the invention. Pro-drugs are usually
(but not
Pro-drug forms of the pharmacologically-active compounds according to the
invention
will generally be compounds according to either formula (I), the
pharmaceutically
group which is esterified or amidated. Included in such esterified acid groups
are
CA 02528849 2005-12-06
-9
groups of the formula ¨COOle, where le is a Ci_6alkyl, phenyl, benzyl or one
of the
following groups:
X
11,11.1
Amidated groups include groups of the formula ¨ CONRYle, wherein RY is H,
Ci_6alkyl, phenyl or benzyl and le is ¨OH, H, Ci_oalkyl, phenyl or benzyl.
Compounds according to the invention having an amino group may be derivatised
with
a ketone or an aldehyde such as formaldehyde to form a Mannich base. This base
will
hydrolyze with first order kinetics in aqueous solution.
Whenever used herein, the term "compounds of formula (I)" is meant to also
include
their N-oxide forms, their addition salts or their stereochemically isomeric
forms. Of
special interest are those compounds of formula (I) which are stereochemically
pure.
A first interesting embodiment of the present invention relates to a compound
of
formula (I-a)
(R6),
R7 R4
R1 OH N, (I-a)
R5
110 R3
Ri N R2
a pharmaceutically acceptable acid or base addition salt thereof, a
stereochemically
isomeric form thereof or a N-oxide form thereof.
A second interesting embodiment of the present invention relates to a compound
of
formula (I-b)
CA 02528849 2005-12-06
-10
(R6),
R4
R7 OH (I-b)
R1
1101 R3 =R5
N R2
a pharmaceutically acceptable acid or base addition salt thereof, a
stereochemically
isomeric form thereof or a N-oxide form thereof.
A third interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein RI
represents
hydrogen, halo, Ci_6alkyl, Ar or Het; preferably hydrogen, halo, optionally
substituted
phenyl or Het; more preferably hydrogen, halo, optionally substituted phenyl,
optionally substituted furanyl, or pyridinyl; even more preferably hydrogen,
halo or
optionally substituted phenyl; most preferred halo, such as for example bromo
or
chloro, in particular bromo.
A fourth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein RI is
halo,
polyhaloCi_6alkyl, Ar or Het; preferably halo, Ar or Het; more preferably
halo,
optionally substituted phenyl, or Het; even more preferably halo, phenyl,
optionally
substituted furanyl, or pyridinyl; most preferred halo or phenyl.
A fifth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R2 is
Ci_6alkyloxy or C1_6alkylthio, in particular methoxy or methylthio; preferably
Ci_6alkyloxy; more preferably methoxy.
A sixth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R3 isAr or
Het
or wherein R3 is Ar or Heti; preferably R3 is Ar; more preferably optionally
substituted
phenyl or optionally substituted naphthyl; even more preferably phenyl
optionally
substituted with halo or Ci_6alkyloxy, or naphthyl optionally substituted with
halo or
Ci_6alkyloxy; most preferably phenyl optionally substituted with 1 or 2 halo,
in
particular fluor , or naphthyl, in particular 1-naphthyl or 2-naphthyl.
CA 02528849 2005-12-06
-11
A seventh interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R4 and R5
each
independently are hydrogen or Ci_6alkyl; or R4 and R5 together and including
the N to
which they are attached may form a radical selected from the group of
pyrrolidinyl,
2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-
imidazolinyl,
2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl,
piperazinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and
thiomorpholinyl, each of
said rings may optionally be substituted with Ci_6alkyl, halo,
polyhaloCi_olkyl,
hydroxy, hydroxyC1_6alkyl, Ci_6alkyloxy, amino, mono- or di(C1_6a1ky1)amino,
C1_6alkylthio, C1_6alkyloxyCl_6alkyl, Ci_6alkylthioCi_6alkyl or pyrimidinyl;
more
preferably R4 is Ci_6alkyl and R5 is hydrogen or Ci_6alkyl; or R4 and R5
together and
including the N to which they are attached may form a radical selected from
the group
of pyffolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl,
pyrazolidinyl,
2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl,
pyridinyl,
piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and
thiomorpholinyl, each of said rings may optionally be substituted with
Ci_6alkyl, halo,
polyhaloCi_6alkyl, hydroxy, hydroxyCi_6alkyl, C1_6alkyloxy, amino, mono- or
di(Ci_6alkyl)amino, C1_6alkylthio, Ci_6alkyloxyCi_6alkyl,
Ci_6alkylthioCi_6alkyl or
pyrimidinyl; even more preferably R4 is Ci_6alkyl and R5 is hydrogen or
Ci_6alkyl; or R4
and R5 together and including the N to which they are attached may form a
radical
selected from the group of pyrrolyl, imidazolyl, pyrazolyl, triazolyl,
piperidinyl,
pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,
morpholinyl and
thiomorpholinyl, each of said rings may optionally be substituted with
C1_6alkyl, halo,
polyhaloCi_6alkyl, hydroxy, hydroxyCi_6alkyl, C1_6alkyloxy, amino, mono- or
di(Ci_6alkyl)amino, C1_6alkylthio, Ci_6alkyloxyCi_6alkyl,
Ci_6alkylthioCi_6alkyl or
pyrimidinyl; most preferably R4 is Ci..6alkyl, in particular methyl or ethyl,
more in
particular methyl, and R5 is hydrogen or Ci_6alkyl, in particular methyl or
ethyl, more in
particular methyl.
An eighth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R4 and R5
each
independently are hydrogen, Ci_6alkyl or benzyl; preferably R4 and R5 each
independently are hydrogen or Ci_6alkyl; more preferably R4 is Ci_6alkyl and
R5 is
hydrogen or Ci_6alkyl; most preferred R4 and R5 are Ci_oalkyl, in particular
methyl or
ethyl, more in particular methyl.
CA 02528849 2005-12-06
-12
A ninth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R4 and R5
together and including the N to which they are attached may form a radical
selected
from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl,
imidazolidinyl,
pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl,
triazolyl,
piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl,
triazinyl,
morpholinyl and thiomorpholinyl, each of said rings may optionally be
substituted with
C1_6alkyl, halo, polyhaloCi_6alkyl, hydroxy, hydroxyC1_6alkyl, Ci_6alkyloxy,
amino,
mono- or di(Ci_6alkyl)amino, Ci_6alkylthio, Ci_6alkyloxyCi_6alkyl,
C1_6alkylthio
Ci_6alkyl or pyrimidinyl; preferably R4 and R5 together and including the N to
which
they are attached may form a radical selected from the group of pyrrolyl,
imidazolyl,
pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl,
pyrimidinyl,
pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, each of said rings may
optionally be substituted with Ci_6alkyl, halo, polyhaloCi_6alkyl, hydroxy,
hydroxyCi_6alkyl, C1_6alkyloxy, amino, mono- or di(Ci_6alkyl)amino,
Ci_6alkylthio,
Ci_6alkyloxyCi_6alkyl, Ci_6alkylthioCi_6alkyl or pyrimidinyl; more preferably
R4 and R5
together and including the N to which they are attached may form a radical
selected
from the group of pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl,
piperazinyl,
morpholinyl and thiomorpholinyl, each of said rings may optionally be
substituted with
6alkyl, halo, polyhaloCi_6alkyl, hydroxy, hydroxyCi_6alkyl, C1_6alkyloxy,
amino,
mono- or di(C1_6alkyl)amino, C1_6alkylthio, Ci_6alkyloxyCl_6alkyl,
Ci_6alkylthioCi_6alkyl or pyrimidinyl; even more preferably R4 and R5 together
and
including the N to which they are attached may form a radical selected from
the group
of imidazolyl, triazolyl, piperidinyl, piperazinyl, morpholinyl and
thiomorpholinyl,
each of said rings may optionally be substituted with Ci_6alkyl, halo,
polyhaloCi_6alkyl,
hydroxy, hydroxyCi_6alkyl, Ci_6alkyloxy, amino, mono- or di(C1_6alkyl)amino,
Ci_6alkylthio, C i6alkyloxyCi 6alkyl, CholkylthioCi_6alkyl or pyrimidinyl;
most
preferred R4 and R5 together and including the N to which they are attached
form
imidazolyl.
Preferably, the substituents on the ring system when R4 and R5 are taken
together, are
selected from Ci_6alkyl, halo, polyhaloCi_6alkyl, hydroxy, C1_6alkyloxy,
C1_6alkylthio
and pyrimidinyl; more preferably the substituents are selected from Ci_6alkyl
or
pyrimidinyl.
A tenth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R6 is
hydrogen,
CA 02528849 2005-12-06
-13
halo, polyhaloC,_6alkyl or Ch6alkyl; or two vicinal R6 radicals may be taken
together to
form a bivalent radical of formula -CH=CH-CH=CH- ; preferably R6 is hydrogen,
halo,
polyhaloCi_6alkyl or Ci_6alkyl; more preferably R6 is hydrogen, halo or
Ci_6alkyl; even
more preferably R6 is hydrogen or halo; most preferred R6 is hydrogen.
An eleventh interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein R7 is
hydrogen.
A twelfth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein r is an
integer
equal to 1.
A thirteenth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein p is an
integer
equal to 1.
A fourteenth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment provided that when
one
RI is Ci_6alkyl then p is an integer equal to 2 and the other RI substituent
is selected
from halo, polyhaloCi_6alkyl, Ci_6alkyl, Ar or Het.
A fifteenth interesting embodiment are the compounds of formula (I) or any
subgroup
thereof as mentioned hereinbefore as interesting embodiment wherein the
compound is
other than (aS, PR)-6-bromo-a12-(dimethylamino)ethy11-2-methoxy-a-1-
naphthaleny1-13-phenyl-3-quinolineethanol, a pharmaceutically acceptable acid
or base
addition salt thereof or a N-oxide form thereof.
A sixteenth interesting embodiment is the use of a compound of formula (I) or
any
subgroup thereof as mentioned hereinbefore as interesting embodiment for the
manufacture of a medicament for the treatment of an infection with a gram-
positive
and/or a gram-negative bacterium.
A seventeenth interesting embodiment is the use of a compound of formula (I)
or any
subgroup thereof as mentioned hereinbefore as interesting embodiment for the
manufacture of a medicament for the treatment of an infection with a gram-
positive
bacterium.
CA 02528849 2005-12-06
-14
An eighteenth interesting embodiment is the use of the compounds of formula
(I) or
any subgroup thereof as mentioned hereinbefore as interesting embodiment for
the
manufacture of a medicament for the treatment of an infection with a gram-
negative
bacterium.
A nineteenth interesting embodiment is the use of a compound of formula (I) or
any
subgroup thereof as mentioned hereinbefore as interesting embodiment for the
manufacture of a medicament for the treatment of a bacterial infection wherein
the
compound of formula (I) has a IC90 < 15 1/m1 against at least one bacterium,
in
particular a gram-positive bacetrium, preferably a IC90 < 101Al/ml, more
preferably a
IC90 < 5 gl/m1; the 1C90 value being determined as described hereinafter.
Also interesting compounds of the present invention are those compounds of
formula
(I) wherein one or more, preferably all, of the following definitions apply:
a) RI is hydrogen; Ci_oalky; halo, in particular bromo or chloro; phenyl;
furanyl
optionally substituted with hydroxyCi_6alkyl; or pyridyl;
b) R2 is Ci_6alkyloxy, in particular methoxy or ethoxy; Ci_oalkylthio, in
particular
methylthio; or C1_6alkyloxyCi_6alkyloxy;
c) R3 is phenyl optionally substituted with 1 or 2 halo, in particular fluoro
or chloro;
naphthyl optionally substituted with 1 or 2 halo or Ci_oalkyloxy; thienyl;
piperidinyl
substituted with Ar-C(=0); 2,3-dihydrobenzo[1,4]dioxinyl; benzo[1,3]dioxoly1;
or
acenaphthyl;
d) R4 and R5 are each independently hydrogen; Ci_oalkyl; benzyl; or R4 and R5
together
and including the N to which they are attached may form a radical selected
from
imidazolyl; pyrazinyl substituted with Cholkyl; piperazinyl substituted with
Ci_6alkyl;
piperazinyl substituted with pyrimidinyl; piperidinyl; thiomorpholinyl;
morpholinyl;
pyrrolidinyl; or triazolyl;
e) R6 is hydrogen; halo, in particular chloro, fluoro or bromo; C1_6alkyl; or
two vicinal
R6 radicals may be taken together to form a bivalent radical of formula
-CH=CH-CH=CH-;
f) R7 is hydrogen.
Preferred compounds of the present invention are compound 50, 206, 31, 26, 27,
32,
33, 109, 39, 44, 41, compound A, E and F, a pharmaceutically acceptable acid
or base
addition salt thereof or a N-oxide form thereof.
CA 02528849 2012-04-25
-15
Another group of preferred compounds are the compounds defined in claim 24,
i.e.compounds 36, 46, 206, 31, 26, 33, 13, 39, 44, Compound A, E and F, a
pharmaceutically acceptable acid or base addition salt thereof or a N-oxide
form
thereof.
The present invention also relates to a compound as claimed in claim 29, i.e.
compounds A, B, C, D, E, F, G, H, I, a pharmaceutically acceptable acid or
base
addition salt thereof or a N-oxide form thereof.
The compounds of formula (I) can be prepared according to the methods
described in
wo 2004/011436.
In general, the compounds according to the invention can be prepared by a
succession
of steps, each of which is known to the skilled person.
In particular, the compounds according to formula (I) can be prepared by
reacting an
intermediate compound of formula (II) with an intermediate compound of formula
MD
according to the following reaction scheme (1) :
Scheme 1
R7
(R1)p (R6)r
r13L-3.1. (1)
s'F15
N
(III)
(II)
using BuLi in a mixture of diisopropyl amine and tetrahydrofuran, and wherein
all
variables are defined as in formula (I). Stirring may enhance the rate of the
reaction.
The reaction may conveniently be carried out at a temperature ranging between
¨20 and
¨70 C.
The starting materials and the intermediate compounds of formula (II) and
(111) are
compounds that are either commercially available or may be prepared according
to
conventional reaction procedures generally known in the art. For example,
intermediate compounds of formula (II-a) may be prepared according to the
following
CA 02528849 2005-12-06
-16
reaction scheme (2):
Scheme 2
(R1)p (R6), 0 (R1)p
(a)
(R6),
\() NH2
N)L-31
1 (b)
(R1)p (R6)r (R1)p (R6)r
(C)
I
I
H-X-Ci_6alkyl N 01
X-01_6a1ky1
(II-a)
wherein all variables are defined as in formula (I). Reaction scheme (2)
comprises step
(a) in which an appropriately substituted aniline is reacted with an
appropriate
acylchloride such as 3-phenylpropionyl chloride, 3-fluorobenzenepropanoyl
chloride or
p-chlorobenzenepropanoyl chloride, in the presence of a suitable base, such as
triethylamine and a suitable reaction-inert solvent, such as methylene
chloride or
ethylene dichloride. The reaction may conveniently be carried out at a
temperature
ranging between room temperature and reflux temperature. In a next step (b)
the
adduct obtained in step (a) is reacted with phosphoryl chloride (POC13) in the
presence
of N,N-dimethylformamide (Vilsmeier-Haack formylation followed by
cyclization).
The reaction may conveniently be carried out at a temperature ranging between
room
temperature and reflux temperature. In a next step (c) a specific R2-group,
wherein R2
is for example an Ci_6alkyloxy or Ci_6alkylthio radical is introduced by
reacting the
intermediate compound obtained in step (b) with a compound H-X-Ci_6alkyl
wherein X
is S or O.
It is evident that in the foregoing and in the following reactions, the
reaction products
may be isolated from the reaction medium and, if necessary, further purified
according
to methodologies generally known in the art, such as extraction,
crystallization and
chromatography. It is further evident that reaction products that exist in
more than one
enantiomeric form, may be isolated from their mixture by known techniques, in
particular preparative chromatography, such as preparative HPLC. Typically,
CA 02528849 2005-12-06
-17
compounds of formula (I) may be separated into their isomeric forms.
The intermediate compounds of formula (III) are compounds that are either
commercially available or may be prepared according to conventional reaction
procedures generally known in the art. For example, intermediate compounds of
formula (III-a) in which R3 is Ar substituted with s substituents RI , wherein
each RI
is independently selected from the group of hydroxy, halo, cyano, nitro,
amino, mono-
or di(C1_6alkyl)amino, Ci_6alkyl, polyhaloCi_6alkyl, Ci_6alkyloxy,
polyhaloCi_6alkyloxy,
carboxyl, Ci_6alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or
di(Ci_6alkyl)aminocarbonyl and s is an integer equal to zero, 1, 2 or 3, may
be prepared
according to the following reaction scheme (3):
Scheme 3
(R10)s Ar 0 (:110)s
\A CI
T (b) (R o)s
-
4
Ar N CI)L CI
(a) -pi.-
R5
(I11-a)
Reaction scheme (3) comprises step (a) in which an appropriately substituted
Ar, in
particular an appropriately substituted phenyl, is reacted by Friedel-Craft
reaction with
an appropriate acylchloride such as 3-chloropropionyl chloride, in the
presence of a
suitable Lewis acid, such as for example A1C13, FeCl3, SnC14, TiC14 or ZnC12
and a
suitable reaction-inert solvent, such as methylene chloride or ethylene
dichloride. The
reaction may conveniently be carried out at a temperature ranging between room
temperature and reflux temperature. In a next step (b) an amino group (-NR4R5)
is
introduced by reacting the intermediate compound obtained in step (a) with
HNR4R5.
In general, bacterial pathogens may be classified as either gram-positive or
gram-
negative pathogens. Antibiotic compounds with activity against both gram-
positive
and gram-negative pathogens are generally regarded as having a broad spectrum
of
activity. The compounds of the present invention are regarded as active
against gram-
positive and/or gram-negative bacterial pathogens. In particular, the present
compounds are active against at least one gram-positive bacterium, preferably
against
several gram-positive bacteria, more preferably against one or more gram-
positive
bacteria and/or one or more gram-negative bacteria.
The present compounds have bactericidal or bacteriostatic activity.
CA 02528849 2005-12-06
-18
Examples of gram-positive and gram-negative aerobic and anaerobic bacteria,
include
Staphylococci, for example S. aureus; Enterococci, for example E. faecalis;
Streptococci, for example S. pneumoniae, S. mutans, S. pyogens; Bacilli, for
example
Bacillus subtilis; Listeria, for example Listeria monocytogenes; Haemophilus,
for
example H. influenza; Moraxella, for example M. catarrhalis; Pseudomonas, for
example Pseudomonas aeruginosa; and Escherichia, for example E. coli.
Gram-positive pathogens, for example Staphylococci, Enterococci and
Streptococci are
particularly important because of the development of resistant strains which
are both
difficult to treat and difficult to eradicate from for example a hospital
environment once
established. Examples of such strains are methicillin resistant Staphylococcus
aureus
(MRSA), methicillin resistant coagulase negative staphylococci (MRCNS),
penicillin
resistant Streptococcus pneumoniae and multiple resistant Enterococcus
faecium.
The compounds of the present invention also show activity against resistant
bacterial
strains.
The compounds of the present invention are especially active against
Staphylococcus
aureus, including resistant Staphylococcus aureus such as for example
methicillin
resistant Staphylococcus aureus (MRSA), and Streptococcus pneumoniae.
In particular, the compounds of the present invention are active on those
bacteria of
which the viability depends on proper functioning of FIFO ATP synthase.
Without
being bound to any theory, it is taught that the activity of the present
compounds lies in
inhibition of the FIFO ATP synthase, in particular the inhibition of the FO
complex of
the FIFO ATP synthase, more in particular the inhibition of subunit c of the
FO
complex of the FIFO ATP synthase, leading to killing of the bacteria by
depletion of
the cellular ATP levels of the bacteria.
Whenever used hereinbefore or hereinafter, that the compounds can treat a
bacterial
infection it is meant that the compounds can treat an infection with one or
more
bacterial strains.
Whenever used hereinbefore or hereinafter, that the bacterial infection is
other than a
Mycobacterial infection it is meant that the bacterial infection is other than
an infection
with one or more Mycobacterial strains.
The exact dosage and frequency of administration of the present compounds
depends
on the particular compound of formula (I) used, the particular condition being
treated,
CA 02528849 2005-12-06
-19
the severity of the condition being treated, the age, weight, gender, diet,
time of
administration and general physical condition of the particular patient, the
mode of
administration as well as other medication the individual may be taking, as is
well
known to those skilled in the art. Furthermore, it is evident that the
effective daily
amount may be lowered or increased depending on the response of the treated
subject
and/or depending on the evaluation of the physician prescribing the compounds
of the
instant invention.
The compound of the present invention may be administered in a
pharmaceutically
acceptable form optionally in a pharmaceutically acceptable carrier. The
compounds
and compositions comprising the compounds can be administered by routes such
as
topically, locally or systemically. Systemic application includes any method
of
introducing the compound into the tissues of the body, e.g., intrathecal,
epidural,
intramuscular, transdermal, intravenous, intraperitoneal, subcutaneous,
sublingual,
rectal, and oral administration. The specific dosage of antibacterial to be
administered,
as well as the duration of treatment, may be adjusted as needed.
Bacterial infections which may be treated by the present compounds include,
for
example, central nervous system infections, external ear infections,
infections of the
middle ear, such as acute otitis media, infections of the cranial sinuses, eye
infections,
infections of the oral cavity, such as infections of the teeth, gums and
mucosa, upper
respiratory tract infections, lower respiratory tract infections,
genitourinary infections,
gastrointestinal infections, gynecological infections, septicemia, bone and
joint
infections, skin and skin structure infections, bacterial endocarditis, burns,
antibacterial
prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed
patients,
such as patients receiving cancer chemotherapy, or organ transplant patients.
Given the fact that the compounds of formula (I) are active against gram-
positive
and/or gram-negative bacteria, the present compounds may be combined with
other
antibacterial agents in order to effectively combat bacterial infections.
Therefore, the present invention also relates to a combination of (a) a
compound of
formula (I), and (b) one or more other antibacterial agents provided that the
one or
more other antibacterial agents are other than antimycobacterial agents.
CA 02528849 2005-12-06
-20
The present invention also relates to a combination of (a) a compound of
formula (I),
and (b) one or more other antibacterial agents provided that the one or more
other
antibacterial agents are other than antimycobacterial agents, for use as a
medicine.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier
and,
as active ingredient, a therapeutically effective amount of (a) a compound of
formula
(I), and (b) one or more other antibacterial agents provided that the one or
more other
antibacterial agents are other than antimycobacterial agents, is also
comprised by the
present invention.
The present invention also relates to the use of a combination or
pharmaceutical
composition as defined above for the treatment of a bacterial infection, in
particular a'
bacterial infection other than a Mycobacterial infection.
The present pharmaceutical composition may have various pharmaceutical forms
for
administration purposes. As appropriate compositions there may be cited all
compositions usually employed for systemically administering drugs. To prepare
the
pharmaceutical compositions of this invention, an effective amount of the
particular
compounds, optionally in addition salt form, as the active ingredient is
combined in
intimate admixture with a pharmaceutically acceptable carrier, which carrier
may take a
wide variety of forms depending on the form of preparation desired for
administration.
These pharmaceutical compositions are desirable in unitary dosage form
suitable, in
particular, for administration orally or by parenteral injection. For example,
in
preparing the compositions in oral dosage form, any of the usual
pharmaceutical media
may be employed such as, for example, water, glycols, oils, alcohols and the
like in the
case of oral liquid preparations such as suspensions, syrups, elixirs,
emulsions and
solutions; or solid carriers such as starches, sugars, kaolin, diluents,
lubricants, binders,
disintegrating agents and the like in the case of powders, pills, capsules and
tablets.
Because of their ease in administration, tablets and capsules represent the
most
advantageous oral unit dosage forms in which case solid pharmaceutical
carriers are
obviously employed. For parenteral compositions, the carrier will usually
comprise
sterile water, at least in large part, though other ingredients, for example,
to aid
solubility, may be included. Injectable solutions, for example, may be
prepared in
which the carrier comprises saline solution, glucose solution or a mixture of
saline and
glucose solution. Injectable suspensions may also be prepared in which case
appropriate liquid carriers, suspending agents and the like may be employed.
Also
CA 02528849 2005-12-06
=
-21
included are solid form preparations which are intended to be converted,
shortly before
use, to liquid form preparations.
Depending on the mode of administration, the pharmaceutical composition will
preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to
70 % by
weight of the active ingredients, and, from 1 to 99.95 % by weight, more
preferably
from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all
percentages
being based on the total composition.
The weight to weight ratio's of the compound of formula (I) and (b) the other
antibacterial agent(s) when given as a combination may be determined by the
person
skilled in the art. Said ratio and the exact dosage and frequency of
administration
depends on the particular compound of formula (I) and the other antibacterial
agent(s)
used, the particular condition being treated, the severity of the condition
being treated,
the age, weight, gender, diet, time of administration and general physical
condition of
the particular patient, the mode of administration as well as other medication
the
individual may be taking, as is well known to those skilled in the art.
Furthermore, it is
evident that the effective daily amount may be lowered or increased depending
on the
response of the treated subject and/or depending on the evaluation of the
physician
prescribing the compounds of the instant invention.
The compounds of formula (I) and the one or more other antibacterial agents
may be
combined in a single preparation or they may be formulated in separate
preparations so
that they can be administered simultaneously, separately or sequentially.
Thus, the
present invention also relates to a product containing (a) a compound of
formula (I),
and (b) one or more other antibacterial agents provided that the one or more
other
antibacterial agents are other than antimycobacterial agents, as a combined
preparation
for simultaneous, separate or sequential use in the treatment of a bacterial
infection.
The pharmaceutical composition may additionally contain various other
ingredients
known in the art, for example, a lubricant, stabilising agent, buffering
agent,
emulsifying agent, viscosity-regulating agent, surfactant, preservative,
flavouring or
colorant.
It is especially advantageous to formulate the aforementioned pharmaceutical
compositions in unit dosage form for ease of administration and uniformity of
dosage.
Unit dosage form as used herein refers to physically discrete units suitable
as unitary
CA 02528849 2005-12-06
-22
dosages, each unit containing a predetermined quantity of active ingredient
calculated
to produce the desired therapeutic effect in association with the required
pharmaceutical carrier. Examples of such unit dosage forms are tablets
(including
scored or coated tablets), capsules, pills, powder packets, wafers,
suppositories,
injectable solutions or suspensions and the like, and segregated multiples
thereof.
The daily dosage of the compound according to the invention will, of course,
vary with
the compound employed, the mode of administration, the treatment desired and
the
bacterial disease indicated.
The other antibacterial agents which may be combined with the compounds of
formula
(I) are antibacterial agents known in the art. The other antibacterial agents
comprise
antibiotics of the (3-lactam group such as natural penicillins, semisynthetic
penicillins,
natural cephalosporins, semisynthetic cephalosporins, cephamycins, 1-
oxacephems,
clavulanic acids, penems, carbapenems, nocardicins, monobactams;
tetracyclines,
anhydrotetracyclines, anthracyclines; aminoglycosides; nucleosides such as
N-nucleosides, C-nucleosides, carbocyclic nucleosides, blasticidin S;
macrolides such
as 12-membered ring macrolides, 14-membered ring macrolides, 16-membered ring
macrolides; ansamycins; peptides such as bleomycins, gramicidins, polymyxins,
bacitracins, large ring peptide antibiotics containing lactone linkages,
actinomycins,
amphomycin, capreomycin, distamycin, enduracidins, mikamycin,
neocarzinostatin,
stendomycin, viomycin, virginiamycin; cycloheximide; cycloserine; variotin;
sarkomycin A; novobiocin; griseofulvin; chloramphenicol; mitomycins;
fumagillin;
monensins; pyrrolnitrin; fosfomycin; fusidic acid; D-(p-hydroxyphenyl)glycine;
D-phenylglycine; enediynes.
Specific antibiotics which may be combined with the present compounds of
formula (I)
are for example benzylpenicillin (potassium, procaine, benzathine),
phenoxymethylpenicillin (potassium), phenethicillin potassium, propicillin,
carbenicillin (disodium, phenyl sodium, indanyl sodium), sulbenicillin,
ticarcillin
disodium, methicillin sodium, oxacillin sodium, cloxacillin sodium,
dicloxacillin,
flucloxacillin, ampicillin, mezlocillin, piperacillin sodium, amoxicillin,
ciclacillin,
hectacillin, sulbactam sodium, talampicillin hydrochloride, bacampicillin
hydrochloride, pivmecillinam, cephalexin, cefaclor, cephaloglycin, cefadroxil,
cephradine, cefroxadine, cephapirin sodium, cephalothin sodium, cephacetrile
sodium,
cefsulodin sodium, cephaloridine, cefatrizine, cefoperazone sodium,
cefamandole,
vefotiam hydrochloride, cefazolin sodium, ceftizoxime sodium, cefotaxime
sodium,
cefmenoxime hydrochloride, cefuroxime, ceftriaxone sodium, ceftazidime,
cefoxitin,
cefmetazole, cefotetan, latamoxef, clavulanic acid, imipenem, aztreonam,
tetracycline,
=
CA 02528849 2005-12-06
-23
chlortetracycline hydrochloride, demethylchlortetracycline, oxytetracycline,
methacycline, doxycycline, rolitetracycline, minocycline, daunorubicin
hydrochloride,
doxorubicin, aclarubicin, kanamycin sulfate, bekanamycin, tobramycin,
gentamycin
sulfate, dibekacin, amikacin, micronomicin, ribostamycin, neomycin sulfate,
paromomycin sulfate, streptomycin sulfate, dihydrostreptomycin, destomycin A,
hygromycin B, apramycin, sisomicin, netilmicin sulfate, spectinomycin
hydrochloride,
astromicin sulfate, validamycin, kasugamycin, polyoxin, blasticidin S,
erythromycin,
erythromycin estolate, oleandomycin phosphate, tracetyloleandomycin,
kitasamycin,
josamycin, spiramycin, tylosin, ivermectin, midecamycin, bleomycin sulfate,
peplomycin sulfate, gramicidin S, polymyxin B, bacitracin, colistin sulfate,
colistinmethanesulfonate sodium, enramycin, mikamycin, virginiamycin,
capreomycin
sulfate, viomycin, enviomycin, vancomycin, actinomycin D, neocarzinostatin,
bestatin,
pepstatin, monensin, lasalocid, salinomycin, amphotericin B, nystatin,
natamycin,
trichomycin, mithramycin, lincomycin, clindamycin, clindamycin palmitate
hydrochloride, flavophospholipol, cycloserine, pecilocin, griseofulvin,
chloramphenicol, chloramphenicol palmitate, mitomycin C, pyrrolnitrin,
fosfomycin,
fusidic acid, bicozamycin, tiamulin, siccanin.
Tables 1 to 4 list compounds of formula (I) according to the present
invention.
Of some compounds the absolute stereochemical configuration of the stereogenic
carbon atom(s) therein was not experimentally determined. In those cases the
stereochemically isomeric form which was first isolated is designated as "A"
and the
second as "B", without further reference to the actual stereochemical
configuration.
However, said "A" and "B" isomeric forms can be unambiguously characterized by
a
person skilled in the art, using art-known methods such as, for example, X-ray
diffraction.
In case "A" and "B" are stereoisomeric mixtures, they can be further separated
whereby the respective first fractions isolated are designated "Al"
respectively "B 1"
and the second as "A2" respectively "B2", without further reference to the
actual
stereochemical configuration. However, said "Al, A2" and "Bl, B2" isomeric
forms
can be unambiguously characterized by a person skilled in the art, using art-
known
methods such as, for example, X-ray diffraction.
Whenever hereinabove or hereinafter, a compound is designated as "A" or "B"
this
means that the compound is a mixture of two enantiomers. Whenever hereinabove
or
CA 02528849 2012-04-25
-24
hereinafter, a compound is designated as "Al", "A2", "B 1" or "B2" this means
that the
compound is an enantiomer.
The relative configuration of the present compounds indicated by erythro and
threo was
determined by
-NMR, performed on a Bruker Avarice 400 MHz (samples were dissolved in CDC13),
by comparing the chemical shifts of a maximum of protons between the different
stereoisomers or by 2D NOESY;
-LCMS performed on a Applied Biosystems API100 Single quadrupole Mass
Spectrometer. Samples were dissolved in a mixture of acetonitrile/methanol and
injected in Flow Injection Analysis mode and analysed in positive electrospray
using a
40V declustering potential. The designation of erythro/threo was based on the
[MH-0
ion peak corresponding to the loss of methanol (resulting from the
fragmentation in the
elctrospray source). When the ion is produced, it is bigger on spectrum of
threo than
on spectrum of erythro compound.
The present compounds are numbered in conformity with the compounds of
WO 2004/011436 and can be prepared according to the methods described in
WO 2004/011436. The Ex. Nr. in the below Tables refer to the Example numbers
of
WO 2004/011436 indicating according to which procedure the compounds can be
prepared.
Additional compounds are indicated by way of letters.
Compound A, B and C were prepared according to the procedures described,in
WO 2004/011436. The scheme below indicates the synthesis pathway of compound
A,
B and C. The Example numbers A8, A9, B12 and B13 correspond to the procedures
of
WO 2004/011436.
*Trademark
CA 02528849 2005-12-06
-25
1101
according to A8 r, according to B12
according to A110 = 9
CI
Intermediate 1
Intermediate 2
H
s
H Br NH
Br
N 0 *
N
according to B13
0
Compound A (B)
Compound C (B) Compound B (A)
Present intermediate 1 was prepared in the same way as intermediate 12 of WO
2004/011436, i.e. according to Example A8 of WO 2004/011436, but starting from
1,3-
difluorobenzene. Yield: 57 % of present intermediate 1.
Present intermediate 2 was prepared in the same way as intermediate 14 of WO
2004/011436, i.e. according to Example A9 of WO 2004/011436, but starting from
present intermediate 1 and reacting it with N-ethylbenzylamine. Yield: 88% of
present
intermediate 2.
Compound C was prepared as follows:
present intermediate 2 was reacted with intermediate compound 3 of WO
2004/011436
in the same way as described in Example B12 of WO 2004/011436. The residue
(5.4g)
obtained according to the procedure of B12, which is a mixture of
diastereoisomers,
was purified by column chromatography over silica gel (eluent:
CH2C12/Cyclohexane:
60/40). Two fractions were collected and the solvent was evaporated. The
second
fraction was crystallized from diisopropylether yielding 0.83g of compound C
(diastereoisomer B) (yield:13 %).
Compounds A and B were prepared as follows:
The residue obtained in the synthesis of compound C was reacted with 1-
chloroethyl
chloroformate in the same way as described in Example B13 of WO 2004/011436.
The residue (1.7g) obtained according to the procedure of Example B13, which
is
mixture of diastereoisomers, was purified by column chromatography over silica
gel
(eluent: CH2C12/CH3OH/NH4OH; 98/2/0.1). Two fractions were collected and the
solvent was evaporated. The fractions were crystallized separately from
CA 02528849 2005-12-06
= ,
-26
diisopropylether yielding 0.31g of compound B (diastereoisomer A) (yield: 27
%) and
0.52g of compound A (diastereoisomer B) (yield:45 %).
Compound D was prepared according to the procedures described in WO
2004/011436.
The scheme below indicates the synthesis pathway of compound D. The Example
numbers A9, B12 and B13 correspond to the procedures of WO 2004/011436.
o o according to B12
according to A9
40 Cl 10 IV/ __________________ w
Ol
intermediate 3
O<H
c
101 IrC H
I
i
Br 0 N I
I Br oio NH
N I
I ei 1\r-
according to B13 1
Compound J
Compound D
Present intermediate 3 was prepared in the same way as intermediate 14 of WO
2004/011436, i.e. according to Example A9 of WO 2004/011436, but starting from
3-
10 chloropropiophenone. Yield: 98 % of present intermediate 3.
Compound J was prepared as follows:
present intermediate 3 was reacted with intermediate compound 3 of WO
2004/011436
in the same way as described in Example B12 of WO 2004/011436. The obtained
residue (4.9g) was purified by column chromatography over silica gel (eluent :
CH2C12). One fraction was collected and the solvent was evaporated. Yield:
1.43g of
compound J, which is a mixture of diastereoisomers.
Compound D was prepared as follows:
compound J was reacted with 1-chloroethyl formate in the same way as described
in
Example B13 of WO 2004/011436. The residue (1.2g) obtained according to the
procedure of Example B13 was purified by column chromatography over silica gel
(eluent: CH2C12/CH3OH/NH4OH; 95/5/0.5). Two fractions were collected and the
solvent was evaporated. The second fraction was crystallized from
diisopropylether
yielding 0.08g of compound D (diastereoisomer B) (yield:10 %).
CA 02528849 2005-12-06
-27
Compounds E and F were prepared by separating compound 4 (diastereoisomer B)
of
WO 2004/011436 into its enantiomers by the following procedure:
Final compound 4 of WO 2004/011436 (2.5g) was separated into its enantiomers
by
column chromatography (eluent: hexane/ethanol 99.95/0.05; column: CHIRACEL
OD). Two pure fractions were collected and their solvents were evaporated.
Yield:
0.5g of compound E (enantiomer B1) (mp. 180 C) and 0.12g of compound F
(enantiomer B2) (mp. 175 C).
Compound G was prepared as follows:
A mixture of compound 115 of WO 2004/011436 (prepared according to B15 of WO
2004/011436) (0.00028 mol), pyridine-3-boronic acid 1,3-propanediol cyclic
ester
(0.00055 mol), Pd[P(Ph3)14 (0.00003 mol) and Na2CO3 2M (0.0011 mol) in
dimethoxyethane (4m1) was stirred at 90 C for 1.5 hours, then poured out into
H20 and
extracted with CH2C12. The organic layer was separated, dried (MgSO4),
filtered and
the solvent was evaporated. The residue was purified by column chromatography
over
silica gel (eluent: CH2C12/CH3OH 95/5; 5 m). The pure fractions were collected
and
the solvent was evaporated. Yield: 0.09g of compound G (60 %) (mp. 201 C).
Compound H was prepared as follows:
A mixture of compound 15 of WO 2004/011436 (prepared according to B7 of WO
2004/011436) (0.0009 mol), 2-furanboronic acid (0.0018 mol), Pd1P(Ph3)14
(0.00009
mol) and Na2CO3 2M (0.0036 mol) in dimethoxyethane (10m1) was stirred at 90 C
for
6 hours, then poured out into H20 and extracted with CH2C12. The organic layer
was
separated, dried (MgSO4), filtered and the solvent was evaporated. The residue
(0.57g)
was purified by column chromatography over silica gel (eluent:
CH2C12/CH3OH/NH4OH 99/1/0.1; 10 m). The pure fractions were collected and the
solvent was evaporated, yielding 0.23g of residue. This fraction was
crystallized from
diisopropylether/acetonitrile. The precipitate was filtered off and dried.
Yield : 0.071g
of compound H (15 %) (mp. 215 C).
Compound! was prepared according to the procedures described in WO
2004/011436.
The scheme below indicates the synthesis pathway of compound I. The Example
numbers A10 and B1 correspond to the procedures of WO 2004/011436.
CA 02528849 2005-12-06
-28
Nz
Br io o
0
intermediate compound 3 HO
HCHO Br
OS of WO 2004/011436 io
H¨N __________________________________________ = N so
Intermediate 4
(A10) (B1)
Compound
A mixture of commercially available 5-acetyl-1,2-dihydroacenaphtylene (0.0407
mol)
and dimethylamine hydrochloride (0.0858 mol) in paraformaldehyde (37 % in
water,
4m1), HC1/iPrOH (1m1) and ethanol (100m1) was stirred and refluxed for 48
hours. The
solvent was evaporated. The residue was taken up in H20/HCI 3N/CH2C12. The
aqueous layer was basified and extracted with CH2C12. The organic layer was
separated, dried (MgSO4), filtered, and the solvent was evaporated. The
residue was
purified by column chromatography over silica gel (eluent: CH2C12/CH3OH/NH4OH
95/5/0.2; 15-40pm). The pure fractions were collected and the solvent was
evaporated.
Yield: 4.9g of intermediate 4 (48 %).
n-BuLi 1.6M (0.0102 mol) was added dropwise at ¨20 C to a solution of
diisopropylamine (0.0091 mol) in tetrahydrofuran (15m1) under N2 flow. The
mixture
was stirred at ¨20 C for 20 minutes, then cooled to ¨70 C. A solution of
intermediate
compound 3 of WO 2004/011436 (0.0091 mol) in tetrahydrofuran (10m1) was added
dropwise. The mixture was stirred at ¨70 C for 2 hours. A solution of present
intermediate 4 (0.01 mol) in tetrahydrofuran (20m1) was added dropwise. The
mixture
was stirred at ¨70 C for 3 hours, poured out into ice water and extracted with
Et0Ac.
The organic layer was separated, dried (MgSO4), filtered, and the solvent was
evaporated. The residue (6.5g) was purified by column chromatography over
silica gel
(eluent: CH2C12/CH3OH/NH4OH 99/1/0.2; 15-40Am). Two fractions were collected
and
the solvent was evaporated. Yield: 0.96g Fl, 0.72g F2. Fl was crystallized
from diethyl
ether. The precipitate was filtered off and dried. Yield: 0.87g of compound
1(17 %).
Table 1:
R6
=H ,CH3
R1 Elo 2
CH3
R3
N R
CA 02528849 2005-12-06
,
-29
, Comp. nr. Ex, RI R2 R3 R6
Stereochemistry and
, nr. melting
points
. _
41 B1 H OCH3 phenyl H , (B); 160 C
_
206 B7 Br OCH3 1-naphthyl F (B) mixture
of 2
- enantiomers is
erythro/syn; 213 C
31 B1 CI OCH3 phenyl H (B) mixture
of 2
enantiomers is
eryhtro/syn; 181 C
26 B1 phenyl OCH3 phenyl H (A) mixture
of 2
enantiomers is threo/anti;
174 C
27 131 phenyl OCH3 phenyl H (B); 192 C
32 Bl Br SCH3 phenyl H (A); 208 C
33 B1 Br SCH3 phenyl H (B) mixture
of 2
enantiomers is
erythro/syn; 196 C
109 B9 I Br OCH3 3-fluorophenyl H (A2); 156
C
39 B9 Br OCH3 3-fluorophenyl H (B)
mixture of 2
enantiomers is
erythro/syn; 207 C
36 B 1 Br OCH3 phenyl CI (A) mixture
of 2
enantiomers is
erythro/syn; 197 C
14 B7 Br OCH3 1-naphthyl H (A); 210 C
15 B7 Br OCH3 1-naphthyl , H (B);
244 C
46 B7 Br OCH3 2-naphthyl H (B) mixture
of 2
enantiomers is
erythro/syn; 162 C
4 131 Br OCH3 phenyl H (B); 190 C
174 B9 )1, OCH3 3-fluorophenyl H (A); 159
C
24 B1 Br OCH3 3-thienyl H (A); 162
C
B2 Br OCH2CH3 phenyl H (A); 162 C
38 B9 I Br OCH3 1 3-fluorophenyl H I (A);
198 C
69 B1 1 Br OCH3 I 2-fluorophenyl H I (A); oil
CA 02528849 2005-12-06
-30
' Comp. nr. Ex. RI R2 R3
R6
Stereochemistry and
nr. melting points
70 B1 Br OCH3 2-fluorophenyl , H .. (Boil
16 131 Br 0C113 4-chlorophenyl .. H .. (A); 200 C
17 131 Br OCH3 4-chlorophenyl .. 1 H 1 .. (B); 190 C
67 88 Br I OCH3 2,5-difluorophenyl I H I
(A); 60 C
116 B15 Br 1 OCH3 3,5-difluorophenyl .. H .. (B); 224 C
159 B8 Br I 0CH3 2,5-difluorophenyl .. H .. (Al); 208
C
160 B8 J Br 0C113 I 2,5-difluorophenyl H
(A2); 167 C
113 B14 Br OCH3 2,3-difluorophenyl .. H .. (A); 128 C
196 B15 Br OCH3 3,4-difluorophenyl .. H .. (B); 184 C
76 B 1 Br OCH3 H (B); 130 C
0
84 B1 phenyl OCH3 1-naphthyl H (A); 248 C
45 I 87 Br OCH3 I 2-naphthyl H (A); 262 C
0
77 B1 Br OCH3 '' IN ) H .. (A); 202 C
0
78 B1 Br OCH3 0
H (B); 202 C
0
,
165 B9 Br
) 3-fluorophenyl H (B); oil
O\
72 B1 Br OCH3 1-naphthyl CH3 (B); 178 C
212 B7 Hoaoiõ OCH3 1-naphthyl H (B); 220 C
163 B7 Br OCH3 6-methoxy-2-naphthyl H (B);
206 C
73 B1 Br OCH, 1-naphthyl Cl (B); 174 C
201 BI Br OCH3
Ur H (A); 214 C
0
30 B1 CI OCH3 phenyl H (A); 170 C
21 B1 Br OCH3 2-thienyl H (B); 176 C
25 B1 Br OCH3 3-thienyl H (B); 160 C
20 B1 Br OCH3 2-thienyl H (A); 96 C
6 B2 Br OCH2CH3 phenyl H (B); 74 C
108 B9 Br OCH3 3-fluorophenyl H (Al); 160 C
37 B1 Br OCH3 phenyl CI (B); 221 C
CA 02528849 2005-12-06
-31
Comp. nr. Ex. RI R2
R3 R6 Stereochemistry and
nr. melting points
13 B7 Br OCH3 1-naphthyl H (A2)
enantiomer is
threo/anti; (1S,2R)120 C
130 B7 Br OCH3 5-bromo-2-naphthyl H (B);
220 C
3-pyridyl OCH3 3,5-difluorophenyl H (A)
mixture of 2
enantiomers is threo/anti;
201 C
2-furanyl 0CH3 1-naphthyl H (B) mixture
of 2
enantiomers is
erythro/syn; 215 C
Br OCH3 (A) mixture
of 2
enantiomers is threo/anti;
111V
>260 C
F B1 Br OCH3 phenyl H (B2)
enantiomer is
erythro/syn ; 175 C
E B1 Br OCH3 phenyl H (B1)
enantiomer is
erythro/syn ; 180 C
Table 2:
R4
= H
R1
R5
F1R2 R3
Comp. nr. Ex. R1 R2
R3 R4 R5 Phys.data
(salt/melting
nr. points) and stereo-
chemistry
44 B4 Br OCH3 phenyl H H (A) mixture of
2
enantiomers is threo/anti;
190 C
19 B1 Br OCH3 phenyl CH2CH3
CH2CH3 .ethanedioate (2:3), (B);
150 C
18 B1 Br OCH3 phenyl CH2CH3
CH2CH3 .ethanedioate (2:3); (A);
230 C
CA 02528849 2005-12-06
,
-32
Table 3
Br OH L
1101 ,- = R3
N =
I ,
Comp. Ex. R3 L Stereochemistry
and melting
nr nr. points
50 B1 phenyl 1-imidazoly1 (B); 230 C
137 B7 2-naphthyl 4-methylpyrazinyl (B); 232 C
154 B7 6-bromo-2-naphthyl 4-methylpiperazinyl I
(B); 254 C
49 B1 phenyl 1-imidazo1y1 (A); 216 C
136 B7 2-naphthyl 4-methylpyrazinyl (A); 188 C
48 I B1 phenyl 1-piperidinyl (B); 210 C
55 B1 phenyl thiomorpholinyl (A); oil
171 B7 2-naphthyl 1-pyrrolidinyl (B); 218 C _
, 129 B1 2-naphthyl 1-piperidinyl (B); 212 C
149 B7 1-nap1'thy1 4-methylpyraziny1 (B); 232 C ,
166 B7 6-bromo-2-naphthyl 1-piperidinyl (B);
218 C
151 B7 3-bromo-l-naphthyl 4-methylpiperazinyl
(A); 178 C
53 B1 Lihenyl 1-(1,2,4-triazoly1) (A); 180 C
,
51 B1 phenyl 1-(4-methyl)piperazinyl (A); 150 C
139 B7 2-napht1?y1 morpholinyl (A); 258 C
140 B7 2-naphthyl morpholinyl (B); 214 C
enantiomers is erythro/syn;
171 C
CA 02528849 2005-12-06
-33
Comp. Ex. R3 L Stereochemistry and
melting
nr. nr. points
B B13 2,4-difluoropheny NH(CH2CH3) (A) mixture of 2
enantiomers is threo/anti
C B12 2,4-difluoropheny N(CH2CH3)(CH2phenyl) (B) mixture of 2
enantiomers is erythro/syn
D B13 phenyl NH(CH3) (B) mixture of 2
enantiomers is erythro/syn;
197 C
209 B7 2-naphthyl (B); 198 C
N
58 B6 phenyl +N (A); 208 C
I \
0-
11 B6 phenyl
+N (B); 208 C
I \
0-
Table 4:
R6
V.
(R1)p\ a = H
b\\, N
R3
c
N
:17omp. Ex. RI R3 R6 Sterechemistry
nr. nr. and melting
points
a
215 B9 H Br CH3 H 3-fluorophenyl H (A);
197 C
226 B7 H Br CH3 H 1-naphthyl H (B); 208
C
229 B7 H CH3 CH3 H 1-naphthyl H (A); 238
C
227 B15 H Br CH3 H 3,5-difluorophenyl H
(A); 195 C
223 B7 H Br H H 1-naphthyl (B); 205 C
3 4
CA 02528849 2012-04-25
-34
Analytical methods
The mass of some compounds was recorded with LCMS (liquid chromatography mass
spectrometry). The method used is described below. The data are gathered in
Table 5
below.
LCMS-method
LCMS analysis was carried out (electrospray ionization in positive mode,
scanning
mode from 100 to 900 amu) on a Kromasil C18 column (Interchim, Monducon, FR; 5
p.m, 4.6 x 150 mm) with a flow rate of 1 ml/minute. Two mobile phases (mobile
phase
A: 30 % 6.5mM ammonium acetate + 40 % acetonitrile + 30 % formic acid (2m1/1);
mobile phase B: 100 % acetonitrile) were employed to run a gradient condition
from
100 % A for 1 minute to 100 % B in 4 minutes, 100 % B for 5 minutes to 100 % A
in 3
minutes, and reequilibrate with 100 % A for 2 minutes.
Table -5 : LCMS parent peak
Compound LCMS parent
No peak (MH+)
A 541
541
631
Pharmacological examples
Preparation of bacterial suspensions for susceptibility testing:
The bacteria used in this study were grown overnight in flasks containing 100
ml
Mueller-Hinton Broth (Becton Dickinson - cat. no. 275730) in sterile de-
ionized water,
with shaking, at 37 C. Stocks (0.5 ml/tube) were stored at ¨70 C until use.
Bacteria
titrations were performed in microtiter plates to detect the TODD, in which
the
TOD50 represents the dilution that gives rise to bacterial growth in 50 % of
inoculated cultures.
In general, an inoculum level of approximately 100 TCID50 was used for
susceptibility
testing.
Anti bacterial Susceptibility testing: IC90 determination
Microtitre plate assay
Flat-bottom, sterile 96-well plastic microtiter plates were filled with 180 I
of sterile
deionized water, supplemented with 0.25 % BSA. Subsequently, stock solutions
(7.8 x
*Trademark
CA 02528849 2005-12-06
-35
final test concentration) of compounds were added in 45 Al volumes in column
2. Serial
five-fold dilutions (45 1 in 180 1) were made directly in the microtiter
plates from
column 2 to reach column 11. Untreated control samples with (column 1) and
without
(column 12) inoculum were included in each microtiter plate. Depending on the
bacteria type, approximately 10 to 60 CFU per well of bacteria inoculum (100
TCID50), in a volume of 100 1 in 2.8x Mueller-Hinton broth medium, was added
to
the rows A to H, except column 12. The same volume of broth medium without
inoculum was added to column 12 in row A to H. The cultures were incubated at
37 C
for 24 hours under a normal atmosphere (incubator with open air valve and
continuous
ventilation). At the end of incubation, one day after inoculation, the
bacterial growth
was quantitated fluorometrically. Therefore resazurin (0.6 mg/ml) was added in
a
volume of 20 1 to all wells 3 hours after inoculation, and the plates were re-
incubated
overnight. A change in colour from blue to pink indicated the growth of
bacteria.
The fluorescence was read in a computer-controlled fluorometer (Cytofluor
Biosearch) at an excitation wavelength of 530 nm and an emission wavelength of
590
nm. The % growth inhibition achieved by the compounds was calculated according
to
standard methods. The IC90 (expressed in g/ml) was defined as the 90 %
inhibitory
concentration for bacterial growth. The results are shown in Table 6.
Agar dilution method.
MIC99 values (the minimal concentration for obtaining 99 % inhibition of
bacterial
growth) can be determined by performing the standard Agar dilution method
according
to NCCLS standards* wherein the media used includes Mueller-Hinton agar.
* Clinical laboratory standard institute. 2005. Methods for dilution
Antimicrobial susceptibility tests for
bacteria that grows Aerobically: approved standard -sixth edition
Time kill assays
Bactericidal or bacteriostatic activity of the compounds may be determined in
a time
kill assay using the broth microdilution method *. In a time kill assay on
Staphylococcus aureus and methicillin resistant S. aureus (MRSA), the starting
inoculum of S. aurues and MRSA is 106 CFU / ml in Muller Hinton broth. The
antibacterial compounds are used at the concentration of 0.1 to 10 times the
MIC (i.e.
IC90 as determined in microtitre plate assay). Wells receiving no
antibacterial agent
constitute the culture growth control. The plates containing the microorganism
and the
test compounds are incubated at 37 c. After 0, 4, 24, and 48 hrs of
incubation samples
are removed for determination of viable counts by serial dilution (104 to 10-
6) in sterile
PBS and plating (200 I) on Mueller Hinton agar. The plates are incubated at
37 C for
CA 02528849 2005-12-06
-36
24 hrs and the number of colonies are determined. Killing curves can be
constructed by
plotting the logi0CFU per ml versus time. A bactericidal effect is commonly
defined as
3-log10 decrease in number of CFU per ml as compared to untreated inoculum.
The
potential carryover effect of the drugs is removed by serial dilutions and
counting the
colonies at highest dilution used for plating.
* Zurenko,G.E. et al. In vitro activities of U-100592 and U-100766, novel
oxazolidinone antibacterial
agents. Antimicrob. Agents Chemother. 40, 839-845 (1996).
Determination of cellular ATP levels
In order to analyse the change in the total cellular ATP concentration ( using
ATP
bioluminescence Kit, Roche), assays are carried out by growing a culture of S.
aureus
(ATCC29213) stock in 100 ml Mueller Hinton flasks and incubate in a shaker-
incubator for 24 hrs at 37 C (300 rpm). Measure 0D405 nm and calculate the
CPU/mi.
Dilute the cultures to 1 x 106 CPU/ml (final concentration for ATP
measurement: 1 x
105 CFU/100 Al per well) and add test compound at 0.1 to 10 times the MIC
(i.e. IC90
as determined in microtitre plate assay). Incubate these tubes for 0, 30 and
60 minutes
at 300 rpm and 37 C. Use 0.6 ml bacterial suspension from the snap-cap tubes
and add
to a new 2 ml eppendorf tubes. Add 0.6 ml cell lysis reagent ( Roche kit),
vortex at
max speed and incubate for 5 minutes at room temperature. Cool on ice. Let the
luminometer warm up to 30 C (Luminoskan Ascent Labsystems with injector). Fill
one
column (= 6 wells) with 100 1 of the same sample. Add 100 Al Luciferase
reagent to
each well by using the injector system. Measure the luminescence for 1 sec.
Table 6 : IC90 values ( g/m1) determined according to the Microtitre plate
assay.
IC90 (pg/m1)
Comp. BSU EGO EFA EFA LMO PAE SMU SPN SPY STA STA STA STA
No. 43639 25922 14506 29212, 49594 27853 33402 6305 8668 43300 25923
29213 RMETH
A 10.8 1.1 10.8 10.8
12.1
50 10.5 10.5 23.6 21.0 26.5
26.5 10.5
41 17.0
22.6 25.3 22.6
206 12.8
31 10.3 4.6 4.1 10.3 10.3 5.2 1.8 11.6
44 7.6 7.6
CA 02528849 2005-12-06
-37
IC90 (pg/m1)
Comp. BSU _ EGO EFA EFA LMO PAE SMU SPN SPY STA STA STA STA
No. 43639 25922 14506 29212 49594 27853 33402 6305 8668 43300 25923 29213
RMETH
26 10.0 4.5 4.5 2.0 11.3
5.6 2.5 11.3 8.9
27 10.0 8.9 12.6
E 12.7 11.3 _ 7.1 10.1 10.1 5.7 5.1 12.7
32 11.7 4.6 4.6 10.4 4.6
_13.1 4.6 13.1 9.3 13.1
33 10.4 _ 11.7 4.6 2.3 11.7 10.4 5.9 2.6 5.9
13.1
109 11.7 9.3 11.7 13.1 13.1 13.1 10.4
39 10.4 4.7 10.4 11.7
5.9 1.9 13.1 10.4
137 21.2 23.8 8.4 21.2
36 24.1 4.8 5.4 4.8 3.8 2.7 0.4
4.8
14 11.1 9.9 5.0 2.5 5.0
12.4 6.2 2.8 5.6 9.9 14.0
15 24.8 24.8 5.0 2.5 12.4 12.4
6.2 2.2 5.0
46 5.0 2.8 5.0 5.6 2.8 0.6
5.6
154 10.9 27.4 27.4 27.4 13.8 24.5
4 12.7
174 10.2
175 10.2 12.8
24 10.2
10.4
38 10.4
69 10.4 10.4 13.1
70 10.4 13.1
49 10.5 10.5 13.3 10.5 5.9 11.8
136 10.6 10.6 10.6
19 13.4
215 10.7
G 13.6 10.8 10.8
16 13.6
17 10.8 0.5
67 10.8 s 13.6
116 10.8
110 10.8 13.6
111 10.8
113 10.8 13.6
CA 02528849 2005-12-06
-38
IC90 (pg/m I)
Comp. BSU ECO EFA _ EFA LMO PAE SMU _SPN SPY STA STA , STA STA
No. 43639 25922 14506 29212 49594 27853 33402 6305 8668 43300 25923 29213
RMETH,
196 10.8
8.6
13.6 13.6
48 10.9 10.9 10.9 13.7 13.7
76 11.0 11.0
84 11.0 11.0 7.0 11.0
45 11.1 12.4
77 11.2 14.2
78 11.2 11.2 11.2
55 0.6
_ 165 14.3 14.3 11.3
72 9.0 14.3 11.4
226 14.3
212 11.4
_ 171 11.6
163 14.7
73 11.8 14.8
129 11.9 15.0 11.9
149 12.2
201 12.3 12.3 12.3 12.3
15.9
18 13.3 13.3 0.7
166 16.9
151 15.4 15.4
30 10.3 10.3 9.2 10.3 , 5.2 10.3
4.9
229 22.5 5.0
21 11.5 4.6 11.5 12.8 12.8
25 11.5 11.5 11.5 12.8 4.1 12.8
20 2.6
6 11.6 11.6 11.6 4.6 13.0 4.6
108 13.1
53 I 5.9
CA 02528849 2005-12-06
-39
IC90 (pg/ml)
Comp. BSU ECO EFA EFA LMO PAE SMU SPN SPY STA STA STA STA
No. 43639 25922 14506 29212 49594 27853 33402 6305 8668 43300 25923 29213
RMETH
37 12.1
47 6.9
227 5.0
13 11.1 11.1 8.8 11.1 2.2 3.5 2.8 8.8 11.1 11.1
51 28.1 25.0 25.0 5.6
11.6
170 26.0
128 9.4
145 23.7 9.4
139 18.9 26.7
140 9.5
223 5.4 13.6 5.4
130 10.1
155 26.9
209 15.1
58 5.9 8.3
11 11.7 10.4 11.7
BSU 43639 means Bacillus subtilis (ATCC43639); ECO 25922 means Escherichia
coli
(ATCC25922); EFA 14506 means Enterococcus faecalis (ATCC14506); EFA 29212
means Enterococcus faecalis (ATCC29212); LMO 49594 means Listeria
monocytogenes (ATCC49594); PAE 27853 means Pseudomonas aeruginosa
(ATCC27853); SMU 33402 means Streptococcus mutans (ATCC33402); SPN 6305
means Streptococcus pneumoniae (ATCC6305); SPY 8668 means Streptococcus
pyogens (ATCC8668); STA 43300 means Staphylococcus aureus (ATCC43300); STA
25923 means Staphylococcus aureus (ATCC25923); STA 29213 means
Staphylococcus aureus (ATCC29213); STA RMETH means methicilline resistant
Staphylococcus aureus (MRSA) (a clinical isolate from the University of
Antwerp).
ATCC means American type tissue culture.
